Monday, December 02, 2019 8:39:44 AM
Regarding the AXSM Momentum(Migraine)Trial: I suspect that, at the least, compliance issues and other trial unknowns have been minimized since the entire trial is being run thru a single company-managed trial site in Miami, Florida.
In addition, considering that this is a triptan study, I think we can assume that none of it's participants have a Cardiovascular Hx. Therefore, since all have had an inadequate Tx response Hx, I think we can also assume that the overwhelming majority(80%+) have failed on triptans, and are likely(at least to some significant degree)to do so here.
As a result, the superior speed & efficacy of the MoSEIC meloxicam component of AXS-07 becomes a critical curve dividing factor, but when combined with the synergistic pharmokinetics of both AXS-07 components, it's a lot easier to imagine how AXS-07's performance in this pt population will significantly outpace standard Riza., standard Meloxicam & placebo at both intervals(2 & 24 hours).
Therefore, although there is always trial risk, the bar, imo, isn't nearly as high as many appear to expect, and the chances for success across the board are very good
In addition, considering that this is a triptan study, I think we can assume that none of it's participants have a Cardiovascular Hx. Therefore, since all have had an inadequate Tx response Hx, I think we can also assume that the overwhelming majority(80%+) have failed on triptans, and are likely(at least to some significant degree)to do so here.
As a result, the superior speed & efficacy of the MoSEIC meloxicam component of AXS-07 becomes a critical curve dividing factor, but when combined with the synergistic pharmokinetics of both AXS-07 components, it's a lot easier to imagine how AXS-07's performance in this pt population will significantly outpace standard Riza., standard Meloxicam & placebo at both intervals(2 & 24 hours).
Therefore, although there is always trial risk, the bar, imo, isn't nearly as high as many appear to expect, and the chances for success across the board are very good
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
